Biopharmaceutical firm PTC Therapeutics has appointed Manal Morsy as vice president of regulatory affairs.
In her new position, Morsy will help the company push forward with development of its clinical candidates as it strives to become a " fully integrated biopharmaceutical company" .
Morsy previously help senior regulatory positions in major pharma companies such as Merck & Co. and Tibotec/J&J. Encysive has scrapped the position of Chief Operating Officer as part of a company-wide restructuring initiative, promoting the former incumbent, George Cole, to the position of President and Chief Executive Officer. Cole, who took on the COO position in November 2005, will be replacing Bruce Given and has also been elected to the company's board of directors.
The company, which has recently been dealt its third approvable letter for its pulmonary arterial hypertension drug Thelin (sitaxsentan) by the US Food and Drug Administration (FDA), has also initiated a restructuring programme which involves a work-force cull of 150 positions, as well as the loss of the COO role.
French firm Novagali Pharma has installed Sylvi Elia-Foeillet as the company's new vice president of pharmaceutical affairs.
Elia-Foeillet will be bring her pharmaceutical and regulatory expertise to bear on the company, which specialises in ophthalmology, structuring and heading up the firm's pharmaceutical affairs department.
Steve Glover is the latest addition to biopharmaceutical firm Insmed , taking on the position of president of the company's newly formed follow-on biologics business.
Glover will be responsible for leading the development of Insmed's follow-on biologics capability and the company's merging portfolio of biogeneric/biosimilar products.
Glover bings 25 years of life-science and biopharmaceutical experience to the role, having formerly held positions at Andrx, Hoffman LaRoche, Amgen and IMS Health.